

# Oncotrace RGCC™

Results



Analysis on a patient test patient 1 suffering from Breast carcinoma stage II.



The sample that was sent to us for analysis was a sample of 20ml Blood that contains anti-coagulant, and packed with an ice pack.

### Laboratory Process

Isolation of malignant cells using flow cytometry with which the circulating tumor cells are enumerated and immunophenotyped

The results during the isolation procedure are presented below

### Table of markers

#### Significant CD45 positive cells (Hematologic origin cells)

CD15

Negative

CD30

Negative

BCR-ABL

Negative

CD34

Negative

CD19

Negative

## CD45 negative cells (non Hematologic origin)

CD34	Negative
CD99	Negative
EpCam	Positive (50% of all CTC) EpCAM+ve: 2.7 cells/7.5 ml
VHL mut	Positive (25% of all CTC)
CD133	Positive (50% of all CTC)
CD44	Negative
Nanog	Positive (75% of all CTC)
OKT-4	Dim
Sox-2	Positive (75% of all CTC)
PSMA	Negative
c-MET	Positive (75% of all CTC)
CD31	Negative
CD19	Negative
MUC-1	Negative
CD63	Negative
panCK	Dim

## Index of markers

CD133, Sox-2*, OKT-4*, Nanog*	Tumor stem cell marker
c-MET*	Membrane antigen that regulates the mesenchymal to epithelial transition
CD34*	Hematological stem cell and blast cell marker, Epithelioid
CD45	Hematologic origin cell
BCR-ABL, CD30	Hematologic malignancy marker
CD44	Tumor stem cell marker
CD15	Hematological malignancy marker
CD19	(CD45 negative cells – Non Hematologic origin cells) lung neuroendocrine malignancy (CD45 positive cells – Hematologic origin cells) Hematological malignancy
CD31	Endothelial cell membrane antigen
CD63	Melanoma cell marker
CD99	Sarcoma marker
EpCam	Epithelial origin marker
MUC-1	Breast cancer antigen
PSMA	Prostate specific cancer stem cell membrane antigen
VHL mut	Renal carcinoma marker
panCK	Epithelial origin cell marker

\* Significant markers

Ioannis Papatiriu M.D., PhD Head of molecular medicine dpt of R.G.C.C -Research Genetic Cancer Centre International GmbH Baarerstr 95, 6300, Zug, Switzerland

Tel: +41-41-7250560 Website: [www.rgcc-group.com](http://www.rgcc-group.com) E-mail: [medical@rgcc-genlab.com](mailto:medical@rgcc-genlab.com)

Patient Name: test patient 1 - Date: 21 Feb 2022

The final results after the isolation procedure are presented below:

We notice that after isolation procedure there are remaining malignant cells.

The concentration of these cells was isolated 3.3 cells/7.5 ml, SD +/- 0.3cells.

### Index of circulating cells number

If over limit: Advanced or progression of disease. If less than limit: Early disease or disease is responding to a treatment plan.

Breast Cancer

< 5 cells / 7.5 ml

Prostate Cancer

< 20 cells / ml

Sarcoma

< 15 cells / 6.5 ml

Colon Cancer

< 5 cells / ml

Lung Cancer

( Lc=0, r=0.99):< 10 cells / ml

All cancer types other than those listed above should be < 5 cells / ml

#### Disclaimers

\*This test will NOT DETECT cancers of the brain or other cancers that have been "encapsulated" by the body, not releasing circulating tumor or stem cells (CTC, CSC) into the blood stream or if any of these cells are dormant. We still recommend the use of biopsy, blood markers and/or various scans with this test when cancer is suspected or known to exist.No test is 100% accurate.

\*The methodology has a sensitivity of 86,2% and specificity of 83,9%

Sincerely,



Ioannis Papatirou MD., PhD Head of molecular medicine dpt. of R.G.C.C.-Research Genetic Cancer Centre International GmbH

Patient Name: test patient 1 - Date: 21 Feb 2022